Research Analysts Issue Forecasts for APLS Q3 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at William Blair upped their Q3 2025 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, July 1st. William Blair analyst L. Hanbury-Brown now expects that the company will earn $1.46 per share for the quarter, up from their prior estimate of ($0.51). The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals' Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at $0.05 EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.77) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $197.61 million. During the same quarter in the prior year, the company earned ($0.54) earnings per share. The business's revenue was down 3.2% compared to the same quarter last year.

Several other research firms have also issued reports on APLS. Raymond James Financial lowered Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and dropped their price objective for the stock from $75.00 to $52.00 in a research note on Friday, May 9th. Citigroup dropped their price objective on Apellis Pharmaceuticals from $49.00 to $41.00 and set a "buy" rating for the company in a research note on Thursday, May 22nd. Robert W. Baird dropped their price objective on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Morgan Stanley increased their price objective on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Finally, Royal Bank Of Canada dropped their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Nine equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $39.79.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock traded up $0.17 during mid-day trading on Friday, hitting $17.99. 891,120 shares of the company were exchanged, compared to its average volume of 2,351,659. The company has a quick ratio of 3.62, a current ratio of 4.08 and a debt-to-equity ratio of 2.76. The business has a fifty day moving average of $18.15 and a 200 day moving average of $23.52. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $42.47. The company has a market capitalization of $2.26 billion, a PE ratio of -10.05 and a beta of 0.67.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $18.77, for a total value of $93,850.00. Following the transaction, the general counsel owned 133,730 shares in the company, valued at $2,510,112.10. This trade represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. boosted its holdings in Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after acquiring an additional 573 shares during the last quarter. Xponance Inc. boosted its holdings in Apellis Pharmaceuticals by 5.6% during the fourth quarter. Xponance Inc. now owns 14,072 shares of the company's stock worth $449,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after buying an additional 758 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in Apellis Pharmaceuticals by 1.6% during the first quarter. Baird Financial Group Inc. now owns 55,529 shares of the company's stock worth $1,214,000 after buying an additional 864 shares during the last quarter. Finally, Woodline Partners LP boosted its holdings in Apellis Pharmaceuticals by 0.5% during the fourth quarter. Woodline Partners LP now owns 189,477 shares of the company's stock worth $6,046,000 after buying an additional 913 shares during the last quarter. Institutional investors own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).